Pharmacological Potential of PDE 5 Inhibitors for the Treatment of Cystic Fibrosis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The High-Affinity cAMP-Specific Phosphodiesterase 8B Controls Steroidogenesis in the Mouse Adrenal Gland

  2011cited by this paper
• Xanthines as adenosine receptor antagonists.

  2011cited by this paper
• Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice

  2010influential reference
• Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation.

  2010cited by this paper
• Vinpocetine inhibits NF-κB–dependent inflammation via an IKK-dependent but PDE-independent mechanism

  2010cited by this paper
• Ataluren (PTC124) Induces CFTR Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis

  2010cited by this paper
• Vinpocetine as a potent antiinflammatory agent

  2010cited by this paper
• Combined usage of inhaled and intravenous milrinone in pulmonary hypertension after heart valve surgery.

  2010cited by this paper
• PDE8 Regulates Rapid Teff Cell Adhesion and Proliferation Independent of ICER

  2010cited by this paper
• Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice.

  2009cited by this paper
• Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice.

  2009cited by this paper
• Comparison of Pharmacokinetics of Vardenafil Administered Using an Ultrasonic Nebulizer for Inhalation vs. a Single 10-mg Oral Tablet.

  2009cited by this paper
• Phosphodiesterase-4 inhibition in COPD.

  2009cited by this paper
• Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats

  2009cited by this paper
• Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.

  2009cited by this paper
• Structural Analog of Sildenafil Identified as a Novel Corrector of the F508del-CFTR Trafficking Defect

  2008cited by this paper
• Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia

  2008cited by this paper
• Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.

  2008influential reference
• Diminished phosphodiesterase-8B potentiates biphasic insulin response to glucose.

  2008cited by this paper
• Paraxanthine, the Primary Metabolite of Caffeine, Provides Protection against Dopaminergic Cell Death via Stimulation of Ryanodine Receptor Channels

  2008cited by this paper
• Correctors Promote Maturation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-processing Mutants by Binding to the Protein*

  2007cited by this paper
• Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

  2007cited by this paper
• Review of current and investigational pharmacologic agents for acute heart failure syndromes.

  2007cited by this paper
• Phosphodiesterase isozymes involved in regulation of HCO3- secretion in isolated mouse duodenum in vitro.

  2007cited by this paper
• N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization.

  2007cited by this paper
• Correctors of Protein Trafficking Defects Identified by a Novel High‐Throughput Screening Assay

  2007cited by this paper
• Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis.

  2007cited by this paper
• CFTR and chaperones

  2007cited by this paper
• Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A

  2006cited by this paper
• Phosphodiesterases in the CNS: targets for drug development

  2006cited by this paper
• Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice

  2006cited by this paper
• Cystic fibrosis since 1938.

  2006cited by this paper
• Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes.

  2006cited by this paper
• Restoration of Neuronal Plasticity by a Phosphodiesterase Type 1 Inhibitor in a Model of Fetal Alcohol Exposure

  2006cited by this paper
• Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

  2006cited by this paper
• Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

  2006cited by this paper
• Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.

  2006cited by this paper
• High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.

  2005cited by this paper
• Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.

  2005cited by this paper
• COPD: current therapeutic interventions and future approaches

  2005cited by this paper
• Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors.

  2005cited by this paper
• Cystic fibrosis.

  2005cited by this paper
• Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.

  2005cited by this paper
• Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.

  2004cited by this paper
• Inhibition of the Phosphodiesterase 4 (PDE4) Enzyme Reverses Memory Deficits Produced by Infusion of the MEK Inhibitor U0126 into the CA1 Subregion of the Rat Hippocampus

  2004cited by this paper
• In-patient major depression: is rolipram as effective as amitriptyline?

  2004cited by this paper
• Sildenafil (Viagra) corrects ΔF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis

  2004influential reference
• Population Dose-Response Model for Tadalafil in the Treatment of Male Erectile Dysfunction

  2004cited by this paper
• Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease.

  2004cited by this paper
• Participation of prostaglandin E receptor EP4 subtype in duodenal bicarbonate secretion in rats.

  2004cited by this paper
• Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.

  2004cited by this paper
• Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

  2004cited by this paper
• Discovery of Thiadiazoles as a Novel Structural Class of Potent and Selective PDE7 Inhibitors. Part 1. Design, Synthesis and Structure—Activity Relationship Studies.

  2004cited by this paper
• Identification of purine inhibitors of phosphodiesterase 7 (PDE7).

  2004cited by this paper
• Theophylline: new perspectives for an old drug.

  2003cited by this paper
• Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.

  2003cited by this paper
• Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain.

  2003cited by this paper
• Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension

  2003cited by this paper
• Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.

  2003cited by this paper
• Tadalafil in the treatment of erectile dysfunction

  2003cited by this paper
• Inhalation therapy: technological milestones in asthma treatment.

  2003cited by this paper
• Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.

  2003cited by this paper
• Tadalafil: a new agent for erectile dysfunction.

  2003cited by this paper
• Treatment of Apnea of Prematurity

  2003cited by this paper
• Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.

  2003cited by this paper
• Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning

  2002cited by this paper
• Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.

  2002cited by this paper
• Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality.

  2002cited by this paper
• Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.

  2002cited by this paper
• Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat.

  2002cited by this paper
• Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.

  2002cited by this paper
• A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction.

  2002cited by this paper
• TADALAFIL (CIALIS™) FOR MEN WITH ERECTILE DYSFUNCTION

  2002cited by this paper
• Cyclic AMP-dependent Cl Secretion Is Regulated by Multiple Phosphodiesterase Subtypes in Human Colonic Epithelial Cells

  2002cited by this paper
• Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

  2002cited by this paper
• T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3

  2001cited by this paper
• Cyclic GMP regulation of the L‐type Ca2+ channel current in human atrial myocytes

  2001cited by this paper
• Cyclic nucleotide phosphodiesterases: relating structure and function.

  2001cited by this paper
• Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: From bench to bedside

  2001cited by this paper
• Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution.

  2001cited by this paper
• Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

  2001cited by this paper
• Vardenafil Increases Penile Rigidity and Tumescence in Men with Erectile Dysfunction after a Single Oral Dose

  2001cited by this paper
• Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues.

  2000cited by this paper
• Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.

  2000cited by this paper
• Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

  2000cited by this paper
• Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase.

  2000cited by this paper
• Molecular diversity of cyclic AMP signalling.

  2000cited by this paper
• Phosphodiesterases and cyclic nucleotide signaling in endocrine cells.

  2000cited by this paper
• Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase.

  2000cited by this paper
• Identification of human PDE7B, a cAMP-specific phosphodiesterase.

  2000cited by this paper
• Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)*

  1999cited by this paper
• Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase.

  1999cited by this paper
• The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects.

  1999cited by this paper
• Differential Expression of the Cyclic GMP-stimulated Phosphodiesterase PDE2A in Human Venous and Capillary Endothelial Cells

  1999cited by this paper
• A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein

  1999cited by this paper
• Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A.

  1999cited by this paper
• Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice.

  1999cited by this paper
• Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases*

  1998cited by this paper
• Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel

  1998cited by this paper
• Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.

  1998cited by this paper

• Pharmacological Potential of PDE5 Inhibitors for the Treatment of Cystic Fibrosis

  2012cites this paper